Affimed Quick Ratio 2014-2024 | AFMDQ
Historical quick ratio values for Affimed (AFMDQ) over the last 10 years.
| Affimed Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2024-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2024-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2024-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2023-12-31 |
$0.09B |
$0.03B |
3.23 |
| 2023-09-30 |
$0.12B |
$0.03B |
3.67 |
| 2023-06-30 |
$0.14B |
$0.03B |
5.03 |
| 2023-03-31 |
$0.18B |
$0.03B |
5.19 |
| 2022-12-31 |
$0.21B |
$0.04B |
5.64 |
| 2022-09-30 |
$0.23B |
$0.04B |
5.63 |
| 2022-06-30 |
$0.27B |
$0.06B |
4.89 |
| 2022-03-31 |
$0.20B |
$0.07B |
3.12 |
| 2021-12-31 |
$0.24B |
$0.08B |
3.19 |
| 2021-09-30 |
$0.24B |
$0.08B |
3.06 |
| 2021-06-30 |
$0.27B |
$0.08B |
3.37 |
| 2021-03-31 |
$0.30B |
$0.08B |
3.93 |
| 2020-12-31 |
$0.17B |
$0.08B |
2.25 |
| 2020-09-30 |
$0.12B |
$0.05B |
2.24 |
| 2020-06-30 |
$0.10B |
$0.04B |
2.91 |
| 2020-03-31 |
$0.10B |
$0.04B |
2.58 |
| 2019-12-31 |
$0.12B |
$0.04B |
3.00 |
| 2019-09-30 |
$0.09B |
$0.03B |
2.72 |
| 2019-06-30 |
$0.10B |
$0.03B |
3.47 |
| 2019-03-31 |
$0.12B |
$0.04B |
3.16 |
| 2018-12-31 |
$0.13B |
$0.04B |
3.00 |
| 2018-09-30 |
$0.05B |
$0.01B |
3.63 |
| 2018-06-30 |
$0.06B |
$0.01B |
5.33 |
| 2018-03-31 |
$0.07B |
$0.01B |
6.55 |
| 2017-12-31 |
$0.05B |
$0.01B |
5.57 |
| 2017-09-30 |
$0.05B |
$0.01B |
6.39 |
| 2017-06-30 |
$0.06B |
$0.01B |
6.65 |
| 2017-03-31 |
$0.06B |
$0.01B |
9.10 |
| 2016-12-31 |
$0.05B |
$0.01B |
7.48 |
| 2016-09-30 |
$0.06B |
$0.01B |
6.24 |
| 2016-06-30 |
$0.07B |
$0.01B |
8.69 |
| 2016-03-31 |
$0.09B |
$0.01B |
8.73 |
| 2015-12-31 |
$0.09B |
$0.01B |
8.73 |
| 2015-09-30 |
$0.07B |
$0.01B |
10.38 |
| 2015-06-30 |
$0.08B |
$0.01B |
13.37 |
| 2015-03-31 |
$0.04B |
$0.01B |
9.23 |
| 2014-12-31 |
$0.05B |
$0.01B |
6.54 |
| 2014-09-30 |
$0.06B |
$0.01B |
7.26 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
